This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Earnings Preview: J&J 1Q To Focus On Newest Drugs

The No More Tears shampoo maker is facing thousands of lawsuits over mesh implants to lift sagging pelvic organs that have caused pain, infection and other complications; painful, recalled artificial hips and a schizophrenia drug, Risperdal, blamed for triggering diabetes. The Justice Department and numerous states have sued J&J over improper marketing of Risperdal, for allegedly downplaying side effects and paying bribes to get nursing homes to put patients on the drug. It turned out to hasten death in elderly people with dementia.

WHY IT MATTERS: J&J has put the worst of its hits from generic competition behind it, is enjoying rising sales from the blood thinner Xarelto and just got another likely blockbuster approved, Invokana. But the product recalls continue, although they're rarer these days.

CEO Alex Gorsky, who took over last April, seems to be enjoying a honeymoon with analysts and investors, who are watching to see how he'll make good on his priorities, particularly fixing the consumer health business.

In December, he brought in a highly regarded Bayer AG exec, Sandra Peterson, to run the division, making her the first outsider ever to join the executive committee that manages J&J.

J&J's stock price had been virtually flat for the decade through last June, limiting its appeal mainly to investors seeking a safe harbor and a strong dividend. But since last June, shares have run up from $62 to just over $82 now. Shares hit an all-time high of $82.95 this month. And suddenly analysts are talking up the stocks of J&J and many big drugmakers.

WHAT'S EXPECTED: Analysts polled by FactSet, on average, expect earnings per share of $1.40 and sales of $17.46 billion.

LAST YEAR'S QUARTER: J&J reported net income of $3.91 billion, or $1.41 per share, on revenue of $16.14 billion.


Follow Linda A. Johnson at

Copyright 2011 Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
2 of 2

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,051.82 -1.89 -0.01%
S&P 500 2,086.97 -1.80 -0.09%
NASDAQ 4,801.1570 -5.7020 -0.12%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs